Answers are grounded in this paper and cite their sources.
This study uses Medicare Part D drug utilization and spending data to estimate potential Part D program and beneficiary savings on brand-name medications excluded by pharmacy benefit managers for which generic substitutes are available.
No takes yet. Share an insight, caveat, or question.
Egilman et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: